Health
Opioid Treatments Expand Across Central Alberta
Officials with Alberta health Services have announced their opioid treatments are expanding across central Alberta. They have shared the following news release outlining those details.
Story by Shelley Rattray
Opioid dependency treatment has been expanded to nine communities throughout Central Alberta.
Alberta Health Services’ (AHS) Rural Opioid Dependency Program has improved access to opioid replacement therapy in Camrose, Drayton Valley, Olds, Ponoka, Rocky Mountain House, Stettler, Sylvan Lake, Wainwright and Wetaskiwin.
“Thanks to the use of video-conferencing technology we are able to provide Albertans with access to programming that normally wouldn’t be possible,” says Dr. Nathaniel Day, Medical Lead for the Rural Opioid Dependency Program.
“It can be difficult to access opioid replacement therapy outside of larger urban centres,” he adds, “however we are able to help eliminate barriers to care by providing video-conferencing sessions between physicians and patients in remote areas.”
The program began accepting patients in April and has the capacity to assist approximately 300 patients.
“Opioid dependency is a growing issue, and we are continuously is working to increase access and availability of substitution treatment,” says Dwight Hunks, Executive Director, Addiction and Mental Health, Central Zone. “This program will help Albertans receive the care they need in their own community. It will help save lives.
“One of the best approaches to treat fentanyl and other opioid addictions is substitution maintenance therapy in addition to counselling and other social support services,” adds Hunks. “This program will help Albertans receive the care they need, closer to home.”
The program was established following the Government of Alberta’s commitment to provide $3 million over three years to expand Opioid Dependency Treatment and increase access to treatment services and counselling across the province.
Since 2016, AHS has also opened a new clinic in Cardston in southwest Alberta, and a satellite clinic in Fort McMurray. More recently, an Opioid Dependency Program launched in Grande Prairie this spring.
Currently, there are now 16 clinics that treat opioid dependency across Alberta. Five of the 16 clinics are provincially funded and delivered by AHS and provide a full range of counselling and support services. A full listing of the clinics can be found on the College of Physicians and Surgeons website.
For more information about Opioid Dependency, please visit www.ahs.ca or call Health Link at 811.
Addictions
B.C. parents powerless to help their addicted teens
B.C. parents say the province’s safer supply program and legal treatment framework leave them powerless to help their addicted teens
On Aug. 19, 2022, Kamilah Sword took a single hydromorphone pill, believing it to be safe. She overdosed and was found dead by her grandmother the next day. She was 14.
Kamilah believed the drug was safe — despite having bought it illicitly — because she was told it came from a government-run “safer supply” program, according to Kamillah’s best friend Grace Miller and her father.
“I’ll never get to see her get married, never have grandkids, never get to see her graduate,” said Kamilah’s father, Gregory Sword, lowering his chin to keep his voice steady.
“It’s a black hole in the heart that never heals.”
Sword faced significant challenges trying to get his daughter help during the year he was aware she was struggling with addiction. He blames British Columbia’s safer supply program and the province’s legal youth treatment framework for exacerbating his daughter’s challenges and ultimately contributing to her death.
“It’s a B.C. law — you cannot force a minor into rehab without their permission,” said Sword. “You cannot parent your kid between the ages of 12 and 18 without their consent.”
Sword is now pursuing legal action against the B.C. and federal governments and several health agencies, seeking accountability for what he views as systemic failures.
B.C.’s “Safe” supply program
B.C.’s prescribed safer supply program, which was first launched in 2020, is designed to reduce substance users’ reliance on dangerous street drugs. Users are prescribed hydromorphone — an opioid as potent as heroin — as an alternative to using potentially lethal street drugs.
However, participants in the program often sell their hydromorphone, in some cases to teenagers, to get money to buy stronger drugs like fentanyl.
According to Grace Miller, she and Kamilah would obtain hydromorphone — which is commonly referred to as Dilaudid or “dillies” — from a teenage friend who bought them in Vancouver’s Downtown Eastside. The neighbourhood, which is the epicentre of Vancouver’s drug crisis, is a 30-minute SkyTrain ride from the teenagers’ home in Port Coquitlam.
Sword says he initially thought “dillies” referred to Dairy Queen’s Dilly Bars. “My daughter would ask me for $5, [and say], ‘Yeah, we’re going to Dairy Queen for a Dilly Bar.’ I had no idea.”
He says he only learned about hydromorphone after the coroner informed him that Kamilah had three substances in her system: cocaine, MDMA and hydromorphone.
“I had to start talking to people to figure out what [hydromorphone] was and where it was coming from.”
Sword is critical of B.C.’s safer supply program for being presented as safe and for lacking monitoring safeguards. “[Kamilah] knew where [the drugs] were coming from so she felt safe because her dealer would keep on telling her, ‘This is safe supply,’” Sword said.
In February, B.C. changed how it refers to the program from “prescribed safer supply” to “prescribed alternatives.”
Grace says another problem with the program is the quantities of drugs being distributed.
“It would be a big difference if the prescriptions that they were giving out were dosed properly,” she said, noting addicts would typically sell bottles containing 14 pills, with pricing starting at $1 a pill.
‘Safer supply’
Sword estimates his daughter struggled with addiction for about 18 to 24 months before her final, fatal overdose.
After Kamilah overdosed for the first time on Aug. 21, 2021, he tried to get her into treatment. A drug counsellor told him that, because she was over 12, she would need to verbally consent. Kamilah refused treatment.
B.C.’s Infants Act allows individuals aged 12 or older to consent to their own medical treatment if they understand the treatment and its implications. The province’s Mental Health Act requires minors aged 12 to 16 to consent to addiction or mental health treatment.
While parents can request involuntary admission for children under 16, a physician or nurse practitioner must first confirm the presence of a mental disorder that requires treatment. No law specifically addresses substance-use disorders in minors.
When Kamilah was admitted to the hospital on one occasion, she underwent a standard psychiatric evaluation and was quickly discharged — despite Sword’s protests.
Ontario also has a mental health law governing involuntary care. Similar to B.C., they permit involuntary care only where a minor has been diagnosed with a mental disorder.
By contrast, Alberta’s Protection of Children Abusing Drugs Act enables a parent or guardian to obtain a court order to place a child under 18 who is struggling with addiction into a secure facility for up to 15 days for detoxification, stabilization and assessment. Alberta is unique among the provinces and territories in permitting involuntary care of minors for substance-use issues.
Grace, who also became addicted to opioids, says her recovery journey involved several failed attempts.
“I never thought I would have almost died so many times,” said Grace, who is now 16. “I never thought I would even touch drugs in my life.”
Grace’s mother Amanda (a pseudonym) faced similar struggles as Sword in trying to get help for her daughter. Amanda says she was repeatedly told nothing more could be done for Grace, because Grace would not consent to treatment.
“One time, [Grace] overdosed at home, and I had to Narcan her because she was dead in her bed,” Amanda said. “I told the paramedic, ‘Our system is broken.’ And she just said, ‘Yes, I know.’”
Yet Grace, who today has been sober for 10 months, would question whether she even had the capacity to consent to treatment when she was addicted to drugs.
Under B.C.’s Health Care (Consent) and Care Facility (Admission) Act, an adult is only considered to have consented to health care if their consent is voluntary, informed, legitimately obtained and the individual is capable of making a decision about their care.
“Mentally able to give consent?” said Grace. “No, I was never really mentally there.”
Subscribe for free to get BTN’s latest news and analysis – or donate to our investigative journalism fund.
System failure
Today, Sword is one of two plaintiffs leading a class-action lawsuit against several provincial and federal health authorities and organizations, including the B.C. Ministry of Health, Health Canada, Vancouver Coastal Health and Vancouver Island Health.
All four of these agencies declined to comment for this story, citing the ongoing court proceedings.
The lawsuit was filed Aug. 15 and is currently awaiting certification to proceed. It alleges the coroner initially identified safer supply drugs as a cause of Kamilah’s death, but later changed the report to omit this reference due to pressure from the province or for other unknown reasons.
It further alleges B.C. and Ottawa were aware that drugs prescribed under safer supply programs were being diverted as early as March 2021, but failed to monitor or control the drugs’ distribution. It points to a Health Canada report and data showing increased opioid-related problems from safer supply programs.
According to Amanda, Kamilah had wanted to overcome her addiction but B.C.’s system failed her.
“I had multiple conversations with Kamilah, and I know Kamilah wanted to get clean,” she says. “But she felt so stuck, like she couldn’t do it, and she felt guilty and ashamed.”
Grace, who battled addiction for four years, is relieved to be sober.
“I’ve never, ever been happier. I’ve never been healthier. It’s the best thing I’ve done for myself,” she said. “It’s just hard when you don’t have your best friend to do it with.”
This article was produced through the Breaking Needles Fellowship Program, which provided a grant to Canadian Affairs, a digital media outlet, to fund journalism exploring addiction and crime in Canada. Articles produced through the Fellowship are co-published by Break The Needle and Canadian Affairs.
Break The Needle. Our content is always free – but if you want to help us commission more high-quality journalism, consider getting a voluntary paid subscription.
Business
US lawmakers accuse Pfizer, Eli Lilly of testing new drugs on prisoners in Communist China
From LifeSiteNews
Two Republicans and two Democrats in the House of Representatives have leveled stunning allegations against two pharmaceutical companies, calling on the U.S. Food and Drug Administration to investigate potential testing of drugs on prisoners of Communist China.
A bipartisan group of Congress members has leveled stunning allegations against pharmaceutical companies Pfizer and Eli Lilly, calling on the U.S. Food & Drug Administration (FDA) to investigate the potential testing of new drugs on prisoners of Communist China.
The letter was sent August 19 to FDA Commissioner Dr. Robert Calf and signed by Select Committee on the Chinese Communist Party (CCP) Chair Rep. John Moolenaar, a Republican from Florida and ranking member and Illinois Democratic Rep. Raja Krishnamoorthi, Health Energy & Commerce Subcommittee ranking member and California Democratic Rep. Anna Eshoo, and Florida Republican Rep. Neal Dunn.
“For over a decade, it appears that U.S. biopharmaceutical companies conducted clinical trials with China’s military organizations, and specifically with medical centers and hospitals affiliated with the People’s Liberation Army’s (PLA), to determine the safety and effectiveness of new drug candidates prior to approval,” the letter reads. “ … we are also concerned that U.S. biopharmaceutical companies have conducted clinical trials with hospital infrastructure located in the Xinjiang Uyghur Autonomous Region (XUAR), where the Chinese Communist Party (CCP) is engaged in genocide of the Uyghur population.”
The lawmakers’ review of publicly available data found that over the last decade major American Pharma companies have conducted “hundreds of clinical trials in China that included at least one entity with PLA in the name as a research trial partner.”
“Even today, one major U.S. biopharmaceutical entity is actively recruiting patients for an advanced Alzheimer drug trial and is partnered with the PLA’s General Hospital and Medical School … and the PLA’s Air Force Medical University. … Previously, another U.S. biopharmaceutical entity used the 307 Hospital of the PLA (307 医院) as the setting for a cancer therapeutic clinical trial.”
Such work not only carries risks of sensitive technology falling into the CCP’s hands, “there are also U.S. biopharmaceutical trials listed on clinicaltrials.gov that were conducted with hospitals located in the XUAR, where credible investigative reports have shown that ethnic minorities in the region are repeatedly forced by the CCP to surrender their body autonomy. As we know, there is simply no ability for firms to conduct due diligence to ensure that clinical trials done in XUAR are voluntary.”
Axios noted that the trials in question concern Pfizer’s kidney cancer drug axitinib (brand name Inlyta), and Eli Lilly’s Alzheimer’s drug donanemab (brand name Kisunla).
The lawmakers asked the FDA to answer several questions related to its knowledge and oversight of such trials and called on the agency to “take on a greater role in protecting U.S. national security interests. With this data, it is clear that the FDA should play a greater role in analyzing U.S. biopharma entities (sic) clinical trial operations in the PRC.”
Pfizer responded that it “is committed to conducting business in an ethical and responsible manner. This includes respecting internationally recognized human rights throughout our operations,” Straight News reported. Eli Lilly claimed that it is “committed to IP protections, and we conduct robust assessments of our partners to ensure they meet Lilly standards for research and data privacy. Further, we oversee their activities when conducting clinical trials to ensure quality and data integrity.”
The allegations come amid a strained public reputation for Big Pharma given its role in the COVID-19 pandemic response.
A large body of evidence has found that mass restrictions on personal and economic activity undertaken in 2020 and part of 2021 caused far more harm than good in terms of personal freedom and economics as well as public health, particularly through the controversial COVID vaccines rushed through development by Pfizer, Moderna, Johnson & Johnson, and the Trump administration.
Yet, so far Big Pharma has largely escaped accountability thanks to the federal Public Readiness and Emergency Preparedness (PREP) Act of 2005. According to the Congressional Research Service (CRS), the PREP Act empowers the federal government to “limit legal liability for losses relating to the administration of medical countermeasures such as diagnostics, treatments, and vaccines.” Near the beginning of the 2020 COVID-19 outbreak, the Trump administration invoked the Act in declaring the virus a “public health emergency.”
Under this “sweeping” immunity, CRS explained, the federal government, state governments, “manufacturers and distributors of covered countermeasures,” and licensed or otherwise-authorized health professionals distributing those countermeasures are shielded from “all claims of loss” stemming from those countermeasures, with the exception of “death or serious physical injury” brought about through “willful misconduct,” a standard that, among other hurdles, requires the offender to have acted “intentionally to achieve a wrongful purpose.”
A handful of states are currently making efforts to hold Pharma companies accountable despite this hurdle, such as Florida’s ongoing grand jury investigation into the vaccines’ manufacturers, and a Kansas lawsuit accusing Pfizer of misrepresentation for calling the shots “safe and effective.”
-
Addictions2 days ago
Harm reduction projects in Nelson are fraying the city’s social fabric, residents say
-
Automotive2 days ago
Ottawa’s tariffs undercut Ottawa’s EV mandate
-
Addictions2 days ago
B.C. parents powerless to help their addicted teens
-
Alberta2 days ago
Alberta bill in the works protects healthcare workers, hospices from having to offer euthanasia
-
Business2 days ago
US lawmakers accuse Pfizer, Eli Lilly of testing new drugs on prisoners in Communist China
-
Crime2 days ago
Trump suggests he’d release Epstein files if re-elected: ‘I’d be inclined to do it’
-
Bruce Dowbiggin2 days ago
Dear Vladdy: Now, A Few Helpful Words From Vladimir Putin
-
National2 days ago
Four years, $10,000, one frog: Inside Parks Canada’s costly frog cull